Literature DB >> 21428177

Therapeutic approach to the malignant tumors of the biliary tract.

Florentina Mihalache1, M Tantău, C Iancu, Raluca Bodea, Angela Părău, Monica Acalovschi.   

Abstract

Cholangiocarcinomas (CCA) are malignant tumors that originate in the cholangiocytes, occur at any level of the biliary tract, are very aggressive and have a 5-year survival rate of 7-8%. Their diagnosis is late and difficult, and the prognosis is very poor. The only curative treatment of these tumors is the complete surgical resection. Signs of unresectability can be detected in most patients with CCA when establishing the diagnosis. Thus, only certain palliative measures can be employed in most cases. The ideal palliative method should be minimally invasive, accompanied by few complications, should offer an increased quality of life, require reduced hospitalization and the lowest costs. The palliative treatment of the obstructive jaundice may be achieved by means of surgical bypass, endoscopic insertion of biliary stents, percutaneous stents, transhepatic stents, photodynamic therapy and/or radio-chemotherapy.

Entities:  

Mesh:

Year:  2010        PMID: 21428177

Source DB:  PubMed          Journal:  Rom J Intern Med        ISSN: 1220-4749


  3 in total

Review 1.  Liver fluke infection and cholangiocarcinoma: a review.

Authors:  Shuohan Zheng; Yuan Zhu; Zijun Zhao; Zhongdao Wu; Kamolnetr Okanurak; Zhiyue Lv
Journal:  Parasitol Res       Date:  2016-10-08       Impact factor: 2.289

Review 2.  Should preoperative biliary drainage be routinely performed for obstructive jaundice with resectable tumor?

Authors:  Chu Wang; Yiyao Xu; Xin Lu
Journal:  Hepatobiliary Surg Nutr       Date:  2013-10       Impact factor: 7.293

3.  Biliary bypass surgery - Analysis of indications & outcome of different procedures.

Authors:  K Altaf Hussain Talpur; Arshad Mahmood Malik; Amir Iqbal Memon; Jawed Naeem Qureshi; Ahmed Khan Sangrasi; Abdul Aziz Laghari
Journal:  Pak J Med Sci       Date:  2013-05       Impact factor: 1.088

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.